Analytical Data
-
Gene name
MED6
- Application
-
Alternative Names
NY-REN-28; ARC33; Activator-recruited cofactor 33 kDa component; Renal carcinoma antigen NY-REN-28; Mediator of RNA polymerase II transcription subunit 6
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75586
-
Expression Region
Met1~Ala235
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MED6, a subunit of the Mediator complex, plays a critical role in regulating gene transcription by serving as a bridge between transcription factors and RNA polymerase II. Research into MED6 has gained traction due to its implications in various biological processes, including cell differentiation, proliferation, and metabolic regulation. Recent studies have linked MED6 to essential pathways in development and disease, particularly in cancer and metabolic disorders. Investigating MED6 recombinant proteins allows scientists to delve deeper into its functional mechanisms, interactions with other proteins, and influence on gene expression. The ability to produce MED6 in recombinant forms facilitates a better understanding of its role within the Mediator complex and its potential as a therapeutic target. Furthermore, the exploration of MED6 variants and post-translational modifications sheds light on its regulatory complexity and suggests avenues for future research into its contribution to cellular homeostasis and pathophysiological conditions.
